1 terminated, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
Follow Pegvorhyaluronidase alfa: new trials by email Literature Review of Pegvorhyaluronidase alfa trials Research Report on Pegvorhyaluronidase alfa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma Pegvorhyaluronidase alfa, Abraxane, Gemcitabine - Pancreatic Ductal Adenocarcinoma | Phase 2 | Withdrawn | Abramson Cancer Center at Penn Medicine | 2020-01-01 | 2020-01-31 | |
| Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma Atezolizumab, PEGPH20 - Pancreatic Ductal Adenocarcinoma | Phase 2 | Terminated | Gulam Manji | 1 | 2019-11-01 | 2020-12-23 |
Abramson Cancer Center at Penn Medicine (1) · Gulam Manji (1)
United States (2)
Gulam Manji, MD, PhD (1) · Thomas Karasic, MD (1)